$CTMX Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in CytomX Therapeutics, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in CytomX Therapeutics, Inc.. Get notifications about new insider transactions in CytomX Therapeutics, Inc. for free.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jun 21 2021 | CTMX | CytomX Therapeutic ... | McCarthy Sean A. | President and CEO | Sell | S | 7.04 | 100,000 | 704,470 | 93,118 | 193.1 K to 93.1 K (-51.78 %) |
Jun 17 2021 | CTMX | CytomX Therapeutic ... | Young Matthew P. | Director | Option Exercise | A | 7.13 | 20,000 | 142,600 | 20,000 | |
Jun 17 2021 | CTMX | CytomX Therapeutic ... | Jones Elaine V | Director | Option Exercise | A | 7.13 | 20,000 | 142,600 | 20,000 | |
Jun 08 2021 | CTMX | CytomX Therapeutic ... | Campoy Carlos | Chief Financial Off ... | Grant | A | 6.09 | 3,320 | 20,206 | 6,421 | 3.1 K to 6.4 K (+107.06 %) |
Apr 02 2021 | CTMX | CytomX Therapeutic ... | McCarthy Sean A. | President and CEO | Option Exercise | M | 1.13 | 100,000 | 113,390 | 92,143 | |
Apr 02 2021 | CTMX | CytomX Therapeutic ... | McCarthy Sean A. | President and CEO | Sell | S | 7.49 | 100,000 | 749,470 | 206,894 | 306.9 K to 206.9 K (-32.58 %) |
Apr 02 2021 | CTMX | CytomX Therapeutic ... | McCarthy Sean A. | President and CEO | Buy | M | 1.13 | 100,000 | 113,390 | 306,894 | 206.9 K to 306.9 K (+48.33 %) |
Mar 02 2021 | CTMX | CytomX Therapeutic ... | Peterson Amy C. | EVP, Chief Developm ... | Option Exercise | A | 7.85 | 250,000 | 1,962,500 | 250,000 | |
Mar 02 2021 | CTMX | CytomX Therapeutic ... | Campoy Carlos | Chief Financial Off ... | Option Exercise | A | 7.85 | 100,000 | 785,000 | 100,000 | |
Mar 02 2021 | CTMX | CytomX Therapeutic ... | HANNAH ALISON L. | Chief Medical Offic ... | Option Exercise | A | 7.85 | 175,000 | 1,373,750 | 175,000 | |
Mar 02 2021 | CTMX | CytomX Therapeutic ... | ROWLAND LLOYD A | General Counsel | Option Exercise | A | 7.85 | 125,000 | 981,250 | 125,000 | |
Mar 02 2021 | CTMX | CytomX Therapeutic ... | McCarthy Sean A. | President and CEO | Option Exercise | A | 7.85 | 200,000 | 1,570,000 | 200,000 | |
Mar 02 2021 | CTMX | CytomX Therapeutic ... | McCarthy Sean A. | President and CEO | Option Exercise | A | 7.85 | 400,000 | 3,140,000 | 400,000 | |
Dec 28 2020 | CTMX | CytomX Therapeutic ... | McCarthy Sean A. | President and CEO | Option Exercise | M | 1.13 | 100,000 | 113,390 | 192,143 | |
Dec 28 2020 | CTMX | CytomX Therapeutic ... | McCarthy Sean A. | President and CEO | Buy | M | 1.13 | 100,000 | 113,390 | 206,894 | 106.9 K to 206.9 K (+93.55 %) |
Dec 18 2020 | CTMX | CytomX Therapeutic ... | Mohindru Mani | Director | Option Exercise | A | 7.45 | 40,000 | 298,000 | 40,000 | |
Dec 07 2020 | CTMX | CytomX Therapeutic ... | Peterson Amy C. | EVP, Chief Developm ... | Grant | A | 6.39 | 3,101 | 19,822 | 3,101 | 0 to 3.1 K |
Dec 07 2020 | CTMX | CytomX Therapeutic ... | McCarthy Sean A. | President and CEO | Grant | A | 6.39 | 930 | 5,945 | 106,894 | 106 K to 106.9 K (+0.88 %) |
Dec 07 2020 | CTMX | CytomX Therapeutic ... | Campoy Carlos | Chief Financial Off ... | Grant | A | 6.39 | 3,101 | 19,822 | 3,101 | 0 to 3.1 K |
Sep 23 2020 | CTMX | CytomX Therapeutic ... | McCarthy Sean A. | President and CEO | Option Exercise | M | 6.61 | 20,500 | 135,601 | 0 | |
Sep 23 2020 | CTMX | CytomX Therapeutic ... | McCarthy Sean A. | President and CEO | Option Exercise | M | 6.61 | 20,500 | 135,601 | 0 | |
Sep 23 2020 | CTMX | CytomX Therapeutic ... | McCarthy Sean A. | President and CEO | Buy | M | 6.61 | 20,500 | 135,601 | 105,964 | 85.5 K to 106 K (+23.99 %) |
Sep 23 2020 | CTMX | CytomX Therapeutic ... | McCarthy Sean A. | President and CEO | Buy | M | 6.61 | 20,500 | 135,601 | 105,964 | 85.5 K to 106 K (+23.99 %) |
Jun 19 2020 | CTMX | CytomX Therapeutic ... | Meyers James R | Director | Option Exercise | A | 8.35 | 20,000 | 167,000 | 20,000 | |
Jun 18 2020 | CTMX | CytomX Therapeutic ... | SCARLETT JOHN A | Director | Option Exercise | A | 8.35 | 20,000 | 167,000 | 20,000 | |
Jun 17 2020 | CTMX | CytomX Therapeutic ... | Young Matthew P. | Director | Option Exercise | A | 8.35 | 20,000 | 167,000 | 20,000 | |
Jun 17 2020 | CTMX | CytomX Therapeutic ... | Jones Elaine V | Director | Option Exercise | A | 8.35 | 20,000 | 167,000 | 20,000 | |
Jun 17 2020 | CTMX | CytomX Therapeutic ... | GLUCK FREDERICK W | Director | Option Exercise | A | 8.35 | 20,000 | 167,000 | 20,000 | |
Jun 17 2020 | CTMX | CytomX Therapeutic ... | Gilbert Halley E | Director | Option Exercise | A | 8.35 | 20,000 | 167,000 | 20,000 | |
Jun 17 2020 | CTMX | CytomX Therapeutic ... | Fuchs Charles S. | Director | Option Exercise | A | 8.35 | 20,000 | 167,000 | 20,000 | |
Jun 02 2020 | CTMX | CytomX Therapeutic ... | McCarthy Sean A. | President and CEO | Grant | A | 5.11 | 1,158 | 5,916 | 85,464 | 84.3 K to 85.5 K (+1.37 %) |
Jun 02 2020 | CTMX | CytomX Therapeutic ... | McCarthy Sean A. | President and CEO | Grant | A | 5.11 | 1,158 | 5,916 | 85,464 | 84.3 K to 85.5 K (+1.37 %) |
Apr 29 2020 | CTMX | CytomX Therapeutic ... | Gilbert Halley E | Director | Option Exercise | A | 9.25 | 40,000 | 370,000 | 40,000 | |
Mar 25 2020 | CTMX | CytomX Therapeutic ... | Campoy Carlos | Chief Financial Off ... | Option Exercise | A | 4.93 | 350,000 | 1,725,500 | 350,000 | |
Feb 21 2020 | CTMX | CytomX Therapeutic ... | Knifsend Robin | Principal Accountin ... | Option Exercise | A | 7.13 | 34,000 | 242,420 | 34,000 | |
Feb 19 2020 | CTMX | CytomX Therapeutic ... | Kavanaugh William Michael | CSO, Head Res.&Non- ... | Option Exercise | A | 7.13 | 120,000 | 855,600 | 120,000 | |
Feb 19 2020 | CTMX | CytomX Therapeutic ... | ROWLAND LLOYD A | General Counsel | Option Exercise | A | 7.13 | 100,000 | 713,000 | 100,000 | |
Feb 19 2020 | CTMX | CytomX Therapeutic ... | Peterson Amy C. | EVP, Chief Developm ... | Option Exercise | A | 7.13 | 25,000 | 178,250 | 25,000 | |
Feb 19 2020 | CTMX | CytomX Therapeutic ... | McCarthy Sean A. | President and CEO | Option Exercise | A | 7.13 | 500,000 | 3,565,000 | 500,000 | |
Feb 05 2020 | CTMX | CytomX Therapeutic ... | HANNAH ALISON L. | Chief Medical Offic ... | Option Exercise | A | 7.71 | 250,000 | 1,927,500 | 250,000 | |
Feb 05 2020 | CTMX | CytomX Therapeutic ... | HANNAH ALISON L. | Chief Medical Offic ... | Option Exercise | A | 7.71 | 250,000 | 1,927,500 | 250,000 | |
Dec 16 2019 | CTMX | CytomX Therapeutic ... | McCarthy Sean A. | President and CEO | Grant | A | 5.32 | 1,080 | 5,747 | 84,306 | 83.2 K to 84.3 K (+1.30 %) |
Oct 16 2019 | CTMX | CytomX Therapeutic ... | Peterson Amy C. | EVP, Chief Developm ... | Option Exercise | A | 7.16 | 400,000 | 2,864,000 | 400,000 | |
Jun 21 2019 | CTMX | CytomX Therapeutic ... | SCARLETT JOHN A | Director | Option Exercise | A | 11.31 | 14,000 | 158,340 | 14,000 | |
Jun 21 2019 | CTMX | CytomX Therapeutic ... | Young Matthew P. | Director | Option Exercise | A | 11.31 | 14,000 | 158,340 | 14,000 | |
Jun 21 2019 | CTMX | CytomX Therapeutic ... | GLUCK FREDERICK W | Director | Option Exercise | A | 11.31 | 14,000 | 158,340 | 14,000 | |
Jun 21 2019 | CTMX | CytomX Therapeutic ... | Fuchs Charles S. | Director | Option Exercise | A | 11.31 | 14,000 | 158,340 | 14,000 | |
Jun 21 2019 | CTMX | CytomX Therapeutic ... | Jones Elaine V | Director | Option Exercise | A | 11.31 | 14,000 | 158,340 | 14,000 | |
Jun 21 2019 | CTMX | CytomX Therapeutic ... | Meyers James R | Director | Option Exercise | A | 11.31 | 14,000 | 158,340 | 14,000 | |
Jun 04 2019 | CTMX | CytomX Therapeutic ... | ROWLAND LLOYD A | General Counsel | Grant | A | 8.21 | 1,812 | 14,878 | 11,791 | 10 K to 11.8 K (+18.16 %) |
Jun 04 2019 | CTMX | CytomX Therapeutic ... | Knifsend Robin | Principal Accountin ... | Grant | A | 8.21 | 1,812 | 14,878 | 2,791 | 979 to 2.8 K (+185.09 %) |
Jun 04 2019 | CTMX | CytomX Therapeutic ... | McCarthy Sean A. | President and CEO | Grant | A | 8.21 | 695 | 5,707 | 83,226 | 82.5 K to 83.2 K (+0.84 %) |
May 02 2019 | CTMX | CytomX Therapeutic ... | Jones Elaine V | Director | Option Exercise | A | 9.35 | 28,000 | 261,800 | 28,000 | |
Apr 10 2019 | CTMX | CytomX Therapeutic ... | GLUCK FREDERICK W | Director | Gift | G | 0.00 | 3,900 | 0 | 18,211 | 22.1 K to 18.2 K (-17.64 %) |
Apr 10 2019 | CTMX | CytomX Therapeutic ... | GLUCK FREDERICK W | Director | Gift | G | 0.00 | 3,900 | 0 | 267,743 | 271.6 K to 267.7 K (-1.44 %) |
Apr 10 2019 | CTMX | CytomX Therapeutic ... | GLUCK FREDERICK W | Director | Gift | G | 0.00 | 3,900 | 0 | 18,211 | 22.1 K to 18.2 K (-17.64 %) |
Apr 10 2019 | CTMX | CytomX Therapeutic ... | GLUCK FREDERICK W | Director | Gift | G | 0.00 | 3,900 | 0 | 267,743 | 271.6 K to 267.7 K (-1.44 %) |
Mar 05 2019 | CTMX | CytomX Therapeutic ... | ROWLAND LLOYD A | General Counsel | Buy | P | 10.33 | 9,000 | 92,970 | 9,979 | 979 to 10 K (+919.31 %) |
Jan 29 2019 | CTMX | CytomX Therapeutic ... | Kavanaugh William Michael | CSO, Head Res.&Non- ... | Option Exercise | A | 16.85 | 90,000 | 1,516,500 | 90,000 | |
Jan 29 2019 | CTMX | CytomX Therapeutic ... | HUMPHREY RACHEL | Chief Medical Offic ... | Option Exercise | A | 16.85 | 90,000 | 1,516,500 | 90,000 | |
Jan 29 2019 | CTMX | CytomX Therapeutic ... | ROWLAND LLOYD A | General Counsel | Option Exercise | A | 16.85 | 54,900 | 925,065 | 54,900 | |
Jan 29 2019 | CTMX | CytomX Therapeutic ... | RAY DEBANJAN | Chief Financial Off ... | Option Exercise | A | 16.85 | 90,000 | 1,516,500 | 90,000 | |
Jan 29 2019 | CTMX | CytomX Therapeutic ... | McCarthy Sean A. | President and CEO | Option Exercise | A | 16.85 | 300,000 | 5,055,000 | 300,000 | |
Dec 27 2018 | CTMX | CytomX Therapeutic ... | Meyers James R | Director | Option Exercise | A | 14.04 | 28,000 | 393,120 | 28,000 | |
Dec 14 2018 | CTMX | CytomX Therapeutic ... | RAY DEBANJAN | Chief Financial Off ... | Option Exercise | M | 1.45 | 3,000 | 4,347 | 7,220 | |
Dec 14 2018 | CTMX | CytomX Therapeutic ... | RAY DEBANJAN | Chief Financial Off ... | Sell | S | 15.00 | 3,000 | 45,000 | 5,928 | 8.9 K to 5.9 K (-33.60 %) |
Dec 14 2018 | CTMX | CytomX Therapeutic ... | RAY DEBANJAN | Chief Financial Off ... | Buy | M | 1.45 | 3,000 | 4,347 | 8,928 | 5.9 K to 8.9 K (+50.61 %) |
Dec 06 2018 | CTMX | CytomX Therapeutic ... | McCarthy Sean A. | President and CEO | Grant | A | 11.73 | 468 | 5,490 | 82,531 | 82.1 K to 82.5 K (+0.57 %) |
Dec 06 2018 | CTMX | CytomX Therapeutic ... | ROWLAND LLOYD A | General Counsel | Grant | A | 11.73 | 979 | 11,484 | 979 | 0 to 979 |
Oct 02 2018 | CTMX | CytomX Therapeutic ... | RAY DEBANJAN | Chief Financial Off ... | Option Exercise | M | 1.45 | 3,000 | 4,347 | 13,220 | |
Oct 02 2018 | CTMX | CytomX Therapeutic ... | RAY DEBANJAN | Chief Financial Off ... | Sell | S | 18.46 | 3,000 | 55,380 | 5,928 | 8.9 K to 5.9 K (-33.60 %) |
Oct 02 2018 | CTMX | CytomX Therapeutic ... | RAY DEBANJAN | Chief Financial Off ... | Buy | M | 1.45 | 3,000 | 4,347 | 8,928 | 5.9 K to 8.9 K (+50.61 %) |
Sep 06 2018 | CTMX | CytomX Therapeutic ... | RAY DEBANJAN | Chief Financial Off ... | Option Exercise | M | 1.45 | 3,000 | 4,347 | 16,220 | |
Sep 06 2018 | CTMX | CytomX Therapeutic ... | RAY DEBANJAN | Chief Financial Off ... | Sell | S | 22.39 | 3,000 | 67,170 | 5,928 | 8.9 K to 5.9 K (-33.60 %) |
Sep 06 2018 | CTMX | CytomX Therapeutic ... | RAY DEBANJAN | Chief Financial Off ... | Buy | M | 1.45 | 3,000 | 4,347 | 8,928 | 5.9 K to 8.9 K (+50.61 %) |
Sep 06 2018 | CTMX | CytomX Therapeutic ... | McCarthy Sean A. | President and CEO | Option Exercise | M | 1.57 | 13,052 | 20,556 | 142,597 | |
Sep 06 2018 | CTMX | CytomX Therapeutic ... | McCarthy Sean A. | President and CEO | Sell | S | 21.86 | 13,052 | 285,343 | 82,063 | 95.1 K to 82.1 K (-13.72 %) |
Sep 06 2018 | CTMX | CytomX Therapeutic ... | McCarthy Sean A. | President and CEO | Buy | M | 1.57 | 13,052 | 20,556 | 95,115 | 82.1 K to 95.1 K (+15.90 %) |
Aug 02 2018 | CTMX | CytomX Therapeutic ... | RAY DEBANJAN | Chief Financial Off ... | Option Exercise | M | 1.45 | 290 | 420 | 19,220 | |
Aug 02 2018 | CTMX | CytomX Therapeutic ... | RAY DEBANJAN | Chief Financial Off ... | Option Exercise | M | 1.45 | 290 | 420 | 19,220 | |
Aug 02 2018 | CTMX | CytomX Therapeutic ... | RAY DEBANJAN | Chief Financial Off ... | Option Exercise | M | 1.26 | 2,710 | 3,414 | 0 | |
Aug 02 2018 | CTMX | CytomX Therapeutic ... | RAY DEBANJAN | Chief Financial Off ... | Option Exercise | M | 1.26 | 2,710 | 3,414 | 0 | |
Aug 02 2018 | CTMX | CytomX Therapeutic ... | RAY DEBANJAN | Chief Financial Off ... | Sell | S | 26.05 | 3,000 | 78,150 | 5,928 | 8.9 K to 5.9 K (-33.60 %) |
Aug 02 2018 | CTMX | CytomX Therapeutic ... | RAY DEBANJAN | Chief Financial Off ... | Sell | S | 26.05 | 3,000 | 78,150 | 5,928 | 8.9 K to 5.9 K (-33.60 %) |
Aug 02 2018 | CTMX | CytomX Therapeutic ... | RAY DEBANJAN | Chief Financial Off ... | Buy | M | 1.45 | 290 | 420 | 8,928 | 8.6 K to 8.9 K (+3.36 %) |
Aug 02 2018 | CTMX | CytomX Therapeutic ... | RAY DEBANJAN | Chief Financial Off ... | Buy | M | 1.45 | 290 | 420 | 8,928 | 8.6 K to 8.9 K (+3.36 %) |
Aug 02 2018 | CTMX | CytomX Therapeutic ... | RAY DEBANJAN | Chief Financial Off ... | Buy | M | 1.26 | 2,710 | 3,414 | 8,638 | 5.9 K to 8.6 K (+45.72 %) |
Aug 02 2018 | CTMX | CytomX Therapeutic ... | RAY DEBANJAN | Chief Financial Off ... | Buy | M | 1.26 | 2,710 | 3,414 | 8,638 | 5.9 K to 8.6 K (+45.72 %) |
Jul 09 2018 | CTMX | CytomX Therapeutic ... | McCarthy Sean A. | President and CEO | Option Exercise | M | 1.57 | 4,497 | 7,082 | 155,649 | |
Jul 09 2018 | CTMX | CytomX Therapeutic ... | McCarthy Sean A. | President and CEO | Sell | S | 25.06 | 4,497 | 112,689 | 82,063 | 86.6 K to 82.1 K (-5.20 %) |
Jul 09 2018 | CTMX | CytomX Therapeutic ... | McCarthy Sean A. | President and CEO | Buy | M | 1.57 | 4,497 | 7,082 | 86,560 | 82.1 K to 86.6 K (+5.48 %) |
Jul 06 2018 | CTMX | CytomX Therapeutic ... | McCarthy Sean A. | President and CEO | Option Exercise | M | 1.57 | 2,028 | 3,194 | 160,146 | |
Jul 06 2018 | CTMX | CytomX Therapeutic ... | McCarthy Sean A. | President and CEO | Sell | S | 25.09 | 2,028 | 50,880 | 82,063 | 84.1 K to 82.1 K (-2.41 %) |
Jul 06 2018 | CTMX | CytomX Therapeutic ... | McCarthy Sean A. | President and CEO | Buy | M | 1.57 | 2,028 | 3,194 | 84,091 | 82.1 K to 84.1 K (+2.47 %) |
Jul 06 2018 | CTMX | CytomX Therapeutic ... | McCarthy Sean A. | President and CEO | Option Exercise | M | 1.57 | 2,028 | 3,194 | 160,146 | |
Jul 06 2018 | CTMX | CytomX Therapeutic ... | McCarthy Sean A. | President and CEO | Sell | S | 25.09 | 2,028 | 50,880 | 82,063 | 84.1 K to 82.1 K (-2.41 %) |
Jul 06 2018 | CTMX | CytomX Therapeutic ... | McCarthy Sean A. | President and CEO | Buy | M | 1.57 | 2,028 | 3,194 | 84,091 | 82.1 K to 84.1 K (+2.47 %) |
Jul 03 2018 | CTMX | CytomX Therapeutic ... | RAY DEBANJAN | Chief Financial Off ... | Option Exercise | M | 1.26 | 3,000 | 3,780 | 2,710 | |
Jul 03 2018 | CTMX | CytomX Therapeutic ... | RAY DEBANJAN | Chief Financial Off ... | Sell | S | 22.56 | 3,000 | 67,680 | 5,928 | 8.9 K to 5.9 K (-33.60 %) |
Jul 03 2018 | CTMX | CytomX Therapeutic ... | RAY DEBANJAN | Chief Financial Off ... | Buy | M | 1.26 | 3,000 | 3,780 | 8,928 | 5.9 K to 8.9 K (+50.61 %) |
Jul 03 2018 | CTMX | CytomX Therapeutic ... | McCarthy Sean A. | President and CEO | Option Exercise | M | 1.57 | 13,052 | 20,556 | 162,174 | |
Jul 03 2018 | CTMX | CytomX Therapeutic ... | McCarthy Sean A. | President and CEO | Sell | S | 23.42 | 13,052 | 305,708 | 82,063 | 95.1 K to 82.1 K (-13.72 %) |
Jul 03 2018 | CTMX | CytomX Therapeutic ... | McCarthy Sean A. | President and CEO | Buy | M | 1.57 | 13,052 | 20,556 | 95,115 | 82.1 K to 95.1 K (+15.90 %) |
Jun 15 2018 | CTMX | CytomX Therapeutic ... | Fuchs Charles S. | Director | Option Exercise | A | 25.25 | 14,000 | 353,500 | 14,000 | |
Jun 15 2018 | CTMX | CytomX Therapeutic ... | Huh Hoyoung | Director | Option Exercise | A | 25.25 | 14,000 | 353,500 | 14,000 | |
Jun 15 2018 | CTMX | CytomX Therapeutic ... | Young Matthew P. | Director | Option Exercise | A | 25.25 | 14,000 | 353,500 | 14,000 | |
Jun 15 2018 | CTMX | CytomX Therapeutic ... | GLUCK FREDERICK W | Director | Option Exercise | A | 25.25 | 14,000 | 353,500 | 14,000 | |
Jun 15 2018 | CTMX | CytomX Therapeutic ... | SCARLETT JOHN A | Director | Option Exercise | A | 25.25 | 14,000 | 353,500 | 14,000 | |
Jun 05 2018 | CTMX | CytomX Therapeutic ... | RAY DEBANJAN | Chief Financial Off ... | Option Exercise | M | 1.26 | 3,000 | 3,780 | 5,710 | |
Jun 05 2018 | CTMX | CytomX Therapeutic ... | RAY DEBANJAN | Chief Financial Off ... | Sell | S | 25.93 | 3,000 | 77,793 | 5,928 | 8.9 K to 5.9 K (-33.60 %) |
Jun 05 2018 | CTMX | CytomX Therapeutic ... | RAY DEBANJAN | Chief Financial Off ... | Buy | M | 1.26 | 3,000 | 3,780 | 8,928 | 5.9 K to 8.9 K (+50.61 %) |
Jun 05 2018 | CTMX | CytomX Therapeutic ... | RAY DEBANJAN | Chief Financial Off ... | Grant | A | 17.90 | 1,187 | 21,248 | 5,928 | 4.7 K to 5.9 K (+25.04 %) |
Jun 05 2018 | CTMX | CytomX Therapeutic ... | McCarthy Sean A. | President and CEO | Grant | A | 17.90 | 302 | 5,406 | 4,945 | 4.6 K to 4.9 K (+6.50 %) |
May 02 2018 | CTMX | CytomX Therapeutic ... | RAY DEBANJAN | Chief Financial Off ... | Option Exercise | M | 1.26 | 3,000 | 3,780 | 8,710 | |
May 02 2018 | CTMX | CytomX Therapeutic ... | RAY DEBANJAN | Chief Financial Off ... | Sell | S | 26.52 | 3,000 | 79,562 | 4,741 | 7.7 K to 4.7 K (-38.75 %) |
May 02 2018 | CTMX | CytomX Therapeutic ... | RAY DEBANJAN | Chief Financial Off ... | Buy | M | 1.26 | 3,000 | 3,780 | 7,741 | 4.7 K to 7.7 K (+63.28 %) |
May 02 2018 | CTMX | CytomX Therapeutic ... | McCarthy Sean A. | President and CEO | Option Exercise | M | 1.57 | 19,578 | 30,833 | 175,226 | |
May 02 2018 | CTMX | CytomX Therapeutic ... | McCarthy Sean A. | President and CEO | Sell | S | 26.55 | 19,578 | 519,743 | 4,643 | 24.2 K to 4.6 K (-80.83 %) |
May 02 2018 | CTMX | CytomX Therapeutic ... | McCarthy Sean A. | President and CEO | Buy | M | 1.57 | 19,578 | 30,833 | 24,221 | 4.6 K to 24.2 K (+421.67 %) |
Apr 04 2018 | CTMX | CytomX Therapeutic ... | RAY DEBANJAN | Chief Financial Off ... | Option Exercise | M | 1.26 | 3,000 | 3,780 | 11,710 | |
Apr 04 2018 | CTMX | CytomX Therapeutic ... | RAY DEBANJAN | Chief Financial Off ... | Sell | S | 28.12 | 3,000 | 84,360 | 4,741 | 7.7 K to 4.7 K (-38.75 %) |
Apr 04 2018 | CTMX | CytomX Therapeutic ... | RAY DEBANJAN | Chief Financial Off ... | Buy | M | 1.26 | 3,000 | 3,780 | 7,741 | 4.7 K to 7.7 K (+63.28 %) |
Mar 27 2018 | CTMX | CytomX Therapeutic ... | GLUCK FREDERICK W | Director | Sell | S | 31.93 | 5,000 | 159,642 | 271,643 | 276.6 K to 271.6 K (-1.81 %) |
Mar 05 2018 | CTMX | CytomX Therapeutic ... | GLUCK FREDERICK W | Director | Sell | S | 30.00 | 16,181 | 485,466 | 276,643 | 292.8 K to 276.6 K (-5.53 %) |
Mar 05 2018 | CTMX | CytomX Therapeutic ... | HUMPHREY RACHEL | Chief Medical Offic ... | Option Exercise | M | 6.61 | 16,160 | 106,894 | 222,980 | |
Mar 05 2018 | CTMX | CytomX Therapeutic ... | HUMPHREY RACHEL | Chief Medical Offic ... | Sell | S | 30.00 | 16,160 | 484,800 | 30,234 | 46.4 K to 30.2 K (-34.83 %) |
Mar 05 2018 | CTMX | CytomX Therapeutic ... | HUMPHREY RACHEL | Chief Medical Offic ... | Buy | M | 6.61 | 16,160 | 106,894 | 46,394 | 30.2 K to 46.4 K (+53.45 %) |
Mar 05 2018 | CTMX | CytomX Therapeutic ... | RAY DEBANJAN | Chief Financial Off ... | Option Exercise | M | 1.13 | 14,485 | 16,425 | 20,000 | |
Mar 05 2018 | CTMX | CytomX Therapeutic ... | RAY DEBANJAN | Chief Financial Off ... | Option Exercise | M | 1.26 | 5,515 | 6,948 | 14,710 | |
Mar 05 2018 | CTMX | CytomX Therapeutic ... | RAY DEBANJAN | Chief Financial Off ... | Option Exercise | M | 1.26 | 13,000 | 16,379 | 20,225 | |
Mar 05 2018 | CTMX | CytomX Therapeutic ... | RAY DEBANJAN | Chief Financial Off ... | Sell | S | 31.02 | 1,944 | 60,293 | 4,741 | 6.7 K to 4.7 K (-29.08 %) |
Mar 05 2018 | CTMX | CytomX Therapeutic ... | RAY DEBANJAN | Chief Financial Off ... | Sell | S | 30.41 | 12,541 | 381,384 | 6,685 | 19.2 K to 6.7 K (-65.23 %) |
Mar 05 2018 | CTMX | CytomX Therapeutic ... | RAY DEBANJAN | Chief Financial Off ... | Buy | M | 1.13 | 14,485 | 16,425 | 19,226 | 4.7 K to 19.2 K (+305.53 %) |
Mar 05 2018 | CTMX | CytomX Therapeutic ... | RAY DEBANJAN | Chief Financial Off ... | Sell | S | 30.06 | 5,515 | 165,775 | 4,741 | 10.3 K to 4.7 K (-53.77 %) |
Mar 05 2018 | CTMX | CytomX Therapeutic ... | RAY DEBANJAN | Chief Financial Off ... | Buy | M | 1.26 | 5,515 | 6,948 | 10,256 | 4.7 K to 10.3 K (+116.33 %) |
Mar 05 2018 | CTMX | CytomX Therapeutic ... | RAY DEBANJAN | Chief Financial Off ... | Sell | S | 29.40 | 13,000 | 382,242 | 4,741 | 17.7 K to 4.7 K (-73.28 %) |
Mar 05 2018 | CTMX | CytomX Therapeutic ... | RAY DEBANJAN | Chief Financial Off ... | Buy | M | 1.26 | 13,000 | 16,379 | 17,741 | 4.7 K to 17.7 K (+274.20 %) |
Mar 02 2018 | CTMX | CytomX Therapeutic ... | HUMPHREY RACHEL | Chief Medical Offic ... | Option Exercise | M | 6.61 | 23,840 | 157,694 | 239,140 | |
Mar 02 2018 | CTMX | CytomX Therapeutic ... | HUMPHREY RACHEL | Chief Medical Offic ... | Sell | S | 30.00 | 23,840 | 715,200 | 30,234 | 54.1 K to 30.2 K (-44.09 %) |
Mar 02 2018 | CTMX | CytomX Therapeutic ... | HUMPHREY RACHEL | Chief Medical Offic ... | Buy | M | 6.61 | 23,840 | 157,694 | 54,074 | 30.2 K to 54.1 K (+78.85 %) |
Mar 02 2018 | CTMX | CytomX Therapeutic ... | GLUCK FREDERICK W | Director | Sell | S | 30.00 | 3,819 | 114,570 | 292,824 | 296.6 K to 292.8 K (-1.29 %) |
Feb 02 2018 | CTMX | CytomX Therapeutic ... | RAY DEBANJAN | Chief Financial Off ... | Sell | S | 26.69 | 2,548 | 68,010 | 4,741 | 7.3 K to 4.7 K (-34.96 %) |
Jan 26 2018 | CTMX | CytomX Therapeutic ... | HUMPHREY RACHEL | Chief Medical Offic ... | Option Exercise | A | 25.82 | 100,000 | 2,582,000 | 100,000 | |
Jan 26 2018 | CTMX | CytomX Therapeutic ... | RAY DEBANJAN | Chief Financial Off ... | Option Exercise | A | 25.82 | 100,000 | 2,582,000 | 100,000 | |
Jan 26 2018 | CTMX | CytomX Therapeutic ... | Kavanaugh William Michael | CSO, Head Res.&Non- ... | Option Exercise | A | 25.82 | 75,000 | 1,936,500 | 75,000 | |
Jan 26 2018 | CTMX | CytomX Therapeutic ... | McCarthy Sean A. | President and CEO | Option Exercise | A | 25.82 | 300,000 | 7,746,000 | 300,000 | |
Jan 09 2018 | CTMX | CytomX Therapeutic ... | McCarthy Sean A. | President and CEO | Option Exercise | M | 1.13 | 6,526 | 7,400 | 337,143 | |
Jan 09 2018 | CTMX | CytomX Therapeutic ... | McCarthy Sean A. | President and CEO | Sell | S | 25.01 | 6,526 | 163,215 | 4,643 | 11.2 K to 4.6 K (-58.43 %) |
Jan 09 2018 | CTMX | CytomX Therapeutic ... | McCarthy Sean A. | President and CEO | Buy | M | 1.13 | 6,526 | 7,400 | 11,169 | 4.6 K to 11.2 K (+140.56 %) |
Jan 08 2018 | CTMX | CytomX Therapeutic ... | GLUCK FREDERICK W | Director | Sell | S | 25.01 | 10,000 | 250,078 | 296,643 | 306.6 K to 296.6 K (-3.26 %) |